Evidence mapPaperPMID 39899133Full record

ArticleActa diabetologica2025

HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment.

Yuta Yamamoto, Katsuya Narumi, Naoko Yamagishi, Yasunori Yonejima, Ken Iseki, Masaki Kobayashi, Yoshimitsu Kanai

Abstract read
In one paragraph

Article in Acta diabetologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuta YamamotoDepartment of Anatomy and Cell Biology, Graduate School of Medical and Pharmaceutical Sciences, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. yuta-y@wakayama-med.ac.jp.ORCID http://orcid.org/0000-0001-5225-6989
Katsuya NarumiLaboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Naoko YamagishiDepartment of Anatomy and Cell Biology, Graduate School of Medical and Pharmaceutical Sciences, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Yasunori YonejimaNoster Inc., Kyoto, Japan.
Ken IsekiLaboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Masaki KobayashiLaboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Yoshimitsu KanaiDepartment of Anatomy and Cell Biology, Graduate School of Medical and Pharmaceutical Sciences, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.

Funding

Noster Inc Noster Inc
6 · The paper itself

Abstract

aimsThe oral administration of linoleic acid immediately before glucose tolerance test (OGTT) ameliorated postprandial hyperglycemia via GPR120 pathway in normal and type 1 diabetes (T1DM) rats. Linoleic acid could promote inflammatory mediators, but 10-hydroxy-cis-12-octadecenoic acid (HYA) converted from linoleic acid by Lactobacillus plantarum has higher GPR120 agonistic activity without promoting inflammatory mediators. This study examined whether the oral-administration of HYA immediately before OGTT also ameliorated the postprandial hyperglycemia in normal rats and T1DM rats injected with bolus insulin.

methodsNormal and T1DM male Sprague-Dawley rats received HYA immediately before OGTT. Other T1DM rats were given HYA and Humulin R immediately before OGTT. We measured the concentration of glucose, insulin, glucagon-like peptide 1 (GLP-1) and cholecystokinin in blood before and after OGTT. We also measured the amount of glucose in the gastric tract after OGTT, and the amount of uptake of methyl-α-D-glucopyranoside in CACO-2 cells.

resultsPostprandial hyperglycemia was ameliorated by HYA in normal rats, and the postprandial blood glucose levels were slowly elevated by HYA in the T1DM model rats. HYA partially inhibited the uptake of methyl-α-D-glucopyranoside in CACO-2 cells. HYA slowed gastric motility and increased the plasma GLP-1 and cholecystokinin levels in normal rats. HYA also ameliorated the postprandial hyperglycemia in T1DM rats given bolus insulin.

conclusionOral administration of HYA immediately before OGTT ameliorated postprandial hyperglycemia through inhibition of glucose absorption and slowing of gastric motility in normal rats. Furthermore, this beneficial effect of HYA was also revealed in T1DM rats injected with bolus insulin.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1HyperglycemiaInsulinLinoleic AcidsAnimalsBlood GlucoseCaco-2 CellsGlucagon-Like Peptide 1Glucose Tolerance TestHumansHypoglycemic AgentsMalePostprandial PeriodRatsRats, Sprague-DawleyBlood GlucoseGlucagon-Like Peptide 1Hypoglycemic AgentsInsulinLinoleic AcidsCCKGLP-1HYAPostprandial hyperglycemiaType 1 diabetes mellitus

Identifiers

PMID39899133
PMCPMC12364981

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.